Literature DB >> 8028615

A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.

M Grompe1, M St-Louis, S I Demers, M al-Dhalimy, B Leclerc, R M Tanguay.   

Abstract

BACKGROUND: Hereditary tyrosinemia type I is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. The disorder clusters in the Saguenay-Lac-St.-Jean area of Quebec. In this region, 1 of 1846 newborns is affected and 1 of every 22 persons is thought to be a carrier. Recently, we identified a splice mutation and two nonsense mutations in the fumarylacetoacetate hydrolase gene in two patients from Quebec with tyrosinemia type I.
METHODS: We used allele-specific-oligonucleotide hybridization to examine the frequency of these three candidate mutations in patients with tyrosinemia type I and in the population of Quebec.
RESULTS: The splice mutation was found in 100 percent of patients from the Saguenay-Lac-St.-Jean area and in 28 percent of patients from other regions of the world. Of 25 patients from the Saguenay-Lac-St.-Jean region, 20 (80 percent) were homozygous for this mutation, a guanine-to-adenine change in the splice-donor sequence in intron 12 of the gene, indicating that it causes most cases of tyrosinemia type I in the region. The frequency of carrier status, based on screening of blood spots from newborns, was about 1 per 25 in the Saguenay-Lac-St.-Jean population and about 1 per 66 overall in Quebec.
CONCLUSIONS: This study identified the most prevalent mutation causing hereditary tyrosinemia in French Canada; it also showed the feasibility of DNA-based testing for carriers in the population at risk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8028615     DOI: 10.1056/NEJM199408113310603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.

Authors:  Shuzhang Yang; Sandra M Siepka; Kimberly H Cox; Vivek Kumar; Marleen de Groot; Yogarany Chelliah; Jun Chen; Benjamin Tu; Joseph S Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  A genomewide linkage-disequilibrium scan localizes the Saguenay-Lac-Saint-Jean cytochrome oxidase deficiency to 2p16.

Authors:  N Lee; M J Daly; T Delmonte; E S Lander; F Xu; T J Hudson; G A Mitchell; C C Morin; B H Robinson; J D Rioux
Journal:  Am J Hum Genet       Date:  2001-01-10       Impact factor: 11.025

3.  Persistent coagulopathy during Escherichia coli sepsis in a previously healthy infant revealed undiagnosed tyrosinaemia type 1.

Authors:  H Georgouli; K H Schulpis; H Michelakaki; M Kaltsa; T Sdogou; L Kossiva
Journal:  BMJ Case Rep       Date:  2010-12-29

4.  Screening for tyrosinaemia type I.

Authors:  A C Hutchesson; S K Hall; M A Preece; A Green
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-05       Impact factor: 5.747

5.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

6.  Cohort Profile: The Saguenay Youth Study (SYS).

Authors:  Zdenka Pausova; Tomas Paus; Michal Abrahamowicz; Manon Bernard; Daniel Gaudet; Gabriel Leonard; Michel Peron; G Bruce Pike; Louis Richer; Jean R Séguin; Suzanne Veillette
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

7.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

8.  Variability of the genetic contribution of Quebec population founders associated to some deleterious genes.

Authors:  E Heyer; M Tremblay
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

9.  Opioid receptor mu 1 gene, fat intake and obesity in adolescence.

Authors:  A Haghighi; M G Melka; M Bernard; M Abrahamowicz; G T Leonard; L Richer; M Perron; S Veillette; C J Xu; C M T Greenwood; A Dias; A El-Sohemy; D Gaudet; T Paus; Z Pausova
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

Review 10.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.